Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Frontotemporal Dementia Clinical Trial

— PROCLAIM  

Official title:

A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04408625
• Other study ID #: J4B-MC-OKAA (PRV-FTD101)
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 9, 2020
• Est. completion date: August 31, 2029

Study information

• Verified date: January 2024
• Source: Prevail Therapeutics
• Contact: Prevail Therapeutics
• Phone: (917) 336-9310
• Email: prevail.patients[@]lilly.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Two escalating dose (low dose and medium dose) cohorts are planned, as well as one bridging cohort which will allocate patients to receive either low or medium dose. The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884963 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will follow up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 23
• Est. completion date: August 31, 2029
• Est. primary completion date: August 31, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 85 Years

Eligibility

Inclusion Criteria:

• Men or women aged 30 to 85 years (inclusive), at the time of informed consent.
• Body weight range of =40 kg (88 lbs) to =110 kg (242 lb) and a BMI of 18 to 34 kg/m2.
• Has symptomatic frontotemporal dementia (FTD), including mild behavioral, cognitive, motor or language impairment per Investigator's assessment (behavioral-variant FTD, primary progressive aphasia-FTD, FTD with corticobasal syndrome, or a combination of syndromes are allowed for enrollment).
• Score =0.5 and =15 on CDR plus NACC FTLD sum of boxes.
• Stable use of background medications at least 8 weeks prior to LY3884963 dosing.
• Carrier of a pathogenic progranulin gene (GRN) mutation.
• Negative screening test for Mycobacterium tuberculosis (MTB) or documented negative MTB test within 1year prior to screening.
• Age- and gender-appropriate cancer screenings are up-to-date and completed.
• Patient and/or patient's legally authorized representative has the ability to understand the purpose and risks of the study, and provide written informed consent and authorization to use protected health information.
• Patient has a reliable study partner/informant (e.g. family member, friend) willing and able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities.
• Patient is not dependent on a walker or wheelchair.
• Patient is living in the community (i.e. not in nursing home); some levels of assisted living may be permitted at the discretion of the investigator.
• Pneumococcal pneumonia and shingles vaccines are required within 10 years of Screening (allowed to be performed during Screening but must be given at least 4 weeks prior to initiation of immunosuppressant regimen).

Exclusion Criteria:

• Diagnosis of a significant CNS (central nervous system) disease other than frontotemporal dementia (FTD) that may cause FTD symptoms or confound study objectives.
• Brain or cervical spine magnetic resonance image (MRI)/MRA imaging showing clinically significant abnormality considered to prevent intracisternal magna (ICM) injection.
• Hypersensitivity or contraindications to corticosteroid, and/or sirolimus use.
• Clinical evidence of peripheral symmetric sensory polyneuropathy (stable sensory mononeuropathies and radiculopathies are not exclusionary).
• Concomitant disease or condition within 6 months of screening that could interfere with, or treatment of which might interfere with, the conduct of the study or that would, in the opinion of the investigator, pose an unacceptable safety risk to the patient or interfere with the patient's ability to comply with study procedures
• Clinically significant laboratory test result abnormalities assessed at screening.
• Participation within 3 months prior to screening in another therapeutic investigational drug or device study with purported disease-modifying effects on FTD, unless it can be documented that the patient received placebo only.
• Any type of prior gene or cell therapy.
• Live vaccines in the 4 weeks prior to Screening. NOTE: Pneumococcal vaccine and/or shingles vaccine administration is allowed at least 4 weeks prior to initiation of immunosuppressant regimen.
• Use of blood thinners in the 2 weeks prior to screening, or anticipated use of blood thinners during the study. Antiplatelet therapies are acceptable if the patient is medically able to temporarily stop 48 hours to 7 days (depending on the antiplatelet medication used) prior to and at least 48 hours after ICM injection and LP. Note: the use of blood thinners as part of prophylaxis or treatment of an emergent VTE or another AE during the study does not exclude the patient, unless there is a baseline high risk of thromboembolic events, and use of blood thinners is highly anticipated in the opinion of the Investigator.
• Contraindications or intolerance to imaging methods (MRA, MRI, and/or computed tomography [CT]), including claustrophobia and intolerance to contrast agents used for MRI, MRA, or CT (including, but not limited to, gadolinium contrast agents and iohexol).
• Contraindications to general anesthesia or deep sedation.
• Positive urine test for drugs of abuse (including opiates, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription at Screening and on Day 1. Other protocol-defined inclusion/exclusion criteria may apply

Related Conditions & MeSH terms

• Aphasia, Primary Progressive
• Dementia
• Frontotemporal Dementia
• Pick Disease of the Brain

Intervention

Biological:
• LY3884963
Participants will receive a single dose of LY3884963, administered intra cisterna magna

Drug:
• Methylprednisolone
IV pulses every 2 weeks in the first 3 months.
• Optional Sirolimus
At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
• Optional Prednisone
If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen

Locations

Country	Name	City	State
Australia	Royal Prince Alfred Hospital, Brain & Mind Research Institute, 94 Mallet Street	Camperdown	New South Wales
Belgium	UZ Leuven, Neurologie Herestraat 49	Leuven
France	Le Ber, Institut du Cerveau et de la Moelle Epinière	Paris
Spain	Hospital Clinic de Barcelona, Villaroel 170 Servicio de Neurología	Barcelona
Spain	Hospital Universitario de Donostia, Servicio De Neurologia, Consultas Externas Neurologia, San Sebastian, Guipúzcoa	San Sebastian
United Kingdom	University College London,Queen Square, Dementia Research Building, London,	London
United States	PPD Phase 1 Clinic, 100 West Gore Street, Suite 202	Orlando	Florida
United States	Hospital of the University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Prevail Therapeutics	Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  France,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation		5 Years
Primary	Sum of adverse reactions (ARs) and suspected ARs		5 years
Primary	Sum of serious ARs and serious suspected ARs		5 years
Primary	Incidence of procedure or treatment-emergent AEs	Measured by brain and spine MRI	5 years
Primary	Change in PGRN immunogenicity in blood	PGRN: progranulin protein. Measured by level of antibodies and ELISPOT	Baseline and Month 12
Primary	Change in PGRN immunogenicity in CSF	CSF: cerebrospinal fluid	Baseline and Month 12
Primary	Change in AAV9 immunogenicity in blood	Measured by level of antibodies and ELISPOT.	Baseline and Month 12
Primary	Change in AAV9, PGRN, and NfL immunogenicity in CSF	Measured by levels of antibodies.	Baseline and Month 12
Primary	Change in PGRN levels in blood		Baseline and Month 12
Primary	Change in PGRN levels in CSF		Baseline and Month 12
Secondary	Change in CDR plus NACC FTLD	CDR: Clinical Dementia Rating staging instrument. NACC FTLD: National Alzheimer's Coordinating Center frontotemporal lobar degeneration domains	Baseline and Month 12
Secondary	Change in NfL levels in blood	NfL: neurofilament light chain	Baseline and Month 12
Secondary	Change in NfL levels in CSF		Baseline and Month 12